Behaviour of vancomycin with the new techniques in haemodialysis;Comportamiento de la vancomicina con las nuevas técnicas de diálisis

Nefrologia

Volumn 25, Issue 5, 2005, Pages 527-534

  Bravo Lopez J J ^a,b   Diaz A ^a   Donado, E ^a   Tarrago J ^a   Tato, F ^a   Romero, R ^a   Sanchez Guisande D ^a   Mardaras, J ^a  

^a Hospital Clinico University de Santiago   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

Author keywords

AFB; Haemodiafiltration; On line; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; BLOOD; HEMODIAFILTRATION; HUMAN; TIME;

ANTI-BACTERIAL AGENTS; HEMODIAFILTRATION; HUMANS; TIME FACTORS; VANCOMYCIN;

EID: 33644869132     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wessler M, Hoen B, Mayeux D, Hestin D, Funtenaille C: Bacteraemia in patients on chronic hemodialysis. A multicenter prespective survey. Nephron 64: 95-100, 1993.
2. Moellering RC, Krogstad DJ, Greenblatt DJ: Pharmacokinetics of vancomycin in normal subjects and in patients wigh reduced renal function. Antimicrob. Rev Infect Dis 3 (Supl.): S230-S235, 1981.
3. Matzke GR, McGory RW, Haltenson LE, Keane WF: Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob. Agents Chemother 25: 433-437, 1984.
4. Brownd L, Muro LS: Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis 11 (1): 15-19, 1988.
5. Moellering RL: Monitoring serum vancomycin levels: climbing the mountain because is it there? Clin infects Dis 18: 544-546, 1994.
6. Edwards DJ, Pancorbos: Routine monitoring of serum Vancomycin concentrations: Waiting for proof of its value. Clin Pharm 6: 652-654, 1987.
7. Keller F, Horstenmeyer L, Looby M, Borner K, Pummer W, Erdman K, Giehl M: Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs 17: 19-26, 1994.
8. Leber HW, Wizeman V, Goubeaud G: Simultaneous hemofiltration/ haemodialysis: an effective alternative to hemofiltration and conventional haemodialysis in the treatment of uremic patients. Clin Nephrol 9: 115, 1978.
9. Ledebo I: Principles and practice of hemofiltration and hemodiafiltration. Artif Organs 22: 20-25, 1998.
10. Galli G, Panzetta G: Acetate free biofiltration (AFB): from theory to clinical results. Clin Nephrol 50: 28-37, 1998.
11. Pedrini LA: On-line Hemodiafiltration: Technique and efficiency. J Nephrol 16 (Supl. 7): S57-S63, 2003.
12. De Francisco ALM, Botella J, Escallada R, Herrnández J, Martín-Malo A, Pérez García R: Hemodiafiltration with sorbent-regenerated ultrafiltrate as replacement fluid: a multicenter study. Nephrol Dial Transplant 12: 528-534, 1997.
13. Barth RH, De Vicenzo N: Use of vancomycin in high-flux haemodialysis: esperience with 130 courses of therapy. Kidney Int 50: 929-936, 1996.
14. Keller F: Vancomycin administration to haemodialysis patients. Clin Nephrol 30: 173, 1988.
15. Bohler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ: Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 42: 625-640, 1992.
16. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ: Vancomycin redistribution: dosing recommendations following high-flux haemodialysis. Kidney Int 45: 232-237, 1994.
17. Foote EF, Dreittlein WB, Seward CA, Kapoian T, Walker SA, Sherman RA: Pharmacokinetics of vancomycin when administered during high flux haemodialysis. Clin Nephrol 50(1): 51-55, 1998.
18. Saunders NJ: Why monitor peak vancomycin concentrations? Lancet 344: 1748-1750, 1994.
19. Ziemniak JA, Cersosimo RJ, Russo J, Moran DM: Rebound following haemodialysis of cimetidine and its metabolites. Am J Kidney Dis 3: 430-435, 1984.
20. Catolico MM, Campbell S, Jones WN, Logan JL: Time course of gentamicin serum concentration rebound following haemodialysis. Drug Intell Clin Pharm 21: 46-49, 1987.
21. Haas T, Dongradi G, Villeboeuf F, De Viel E, Fournier JF, Durvy D: Plasma kinetics of small molecules during and after haemofiltration: Decrease in haemofiltration efficacy related to increase in ultrafiltration rate. Clin Nephrol 19: 193-200, 1983.
22. Keller F, Offerman G, Schoke J: Kinetics of the redistribution phenomenon after extracorporeal elimination. I nt J Artif Organs 7: 181-188, 1984.
23. Gibson TP: Problems in designing haemodialysis drug studies. Pharmacotherapy 5: 23-29, 1985.
24. Desoi CA, Sahm DF, Umans JG: Vancomycin elimination during high-flux haemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 20: 354-360, 1992.
25. Frigon RP, Leypoldt Jk, Alford MF, Uyeji S, Henderson LW: hemofilter solute sieving is not governed by dynamicalliy polarized protein. Trans Am. Artif. Intern. Ogans 30: 486-490, 1984.
26. Langsdorf LJ, Zydney AL: diffusive and convective solute transport through haemodialysis membranes: a hydrodynamic analysis. J Biomed Materials Res 28: 573-572, 1994.
27. Scott MK, Mueller BA, Llark WR: vancomycin mass transfec characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 12: 2647-2653, 1997.
28. 2- microglobulin removal between cellulosic and syntethic polymer membrane dialyzers. Trans Am Soc Artif Intern Organs 36: 643-646, 1990.
29. 2-microglobulin during haemodialysis using polysulfone, polyacrylonitrile, polymethymethacrylate, and cuprammonium rayon membranes. Int J Artif Organs 12: 697-702, 1989.
30. Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA: Falsely elevated serum vancomycin concentrations in haemodialysis patients. Am J Kidney Dis 27: 67-74, 1996.
31. Freeman CD, Quintiliani R, Nightingale CH: Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 27: 594-598, 1993.